

DAFTAR PUSTAKA

- ABDEL-ALEEM, H., D'ARCANGUES, C., VOGELSONG, K. & GULMEZOGLU, A. M. 2007. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. *Cochrane Database Syst Rev*, CD003449.
- ALI, D. A. & SAEED, A. M. 2019. Anti-Mullerian hormone (AMH) and antral follicular count after prolonged use of hormonal contraception. *Evidence Based Women's Health Journal*, 9, 585-590.
- ALIPOUR, F., RASEKHJAHROMI, A., MAALHAGH, M., SOBHANIAN, S. & HOSSEINPOOR, M. 2015. Comparison of Specificity and Sensitivity of AMH and FSH in Diagnosis of Premature Ovarian Failure. *Dis Markers*, 2015, 585604.
- ALMOG, B., SHEHATA, F., SUISSA, S., HOLZER, H., SHALOM-PAZ, E., LA MARCA, A., MUTTUKRISHNA, S., BLAZAR, A., HACKETT, R., NELSON, S. M., CUNHA-FILHO, J. S., ELDAR-GEVA, T., MARGALIOH, E. J., RAINE-FENNING, N., JAYAPRAKASAN, K., MCILVEEN, M., WUNDER, D., FREOUR, T., NARDO, L. G., BALASCH, J., PENARRUBIA, J., SMEENK, J., GNOTH, C., GODEHARDT, E., LEE, T. H., LEE, M. S., LEVIN, I., GAMZU, R. & TULANDI, T. 2011. Age-related normograms of serum antimullerian hormone levels in a population of infertile women: a multicenter study. *Fertil Steril*, 95, 2359-63, 2363 e1.
- ALVAREZ, F., BRACHE, V., FAUNDES, A., JORGE, A. & SOUSA, M. H. 2003. Local side effects observed among long-term users of norplant contraceptive implants. *Contraception*, 68, 111-5.
- AMER, S. 2020. *Ovarian reserve: current trends and applications*, Nova Medicine and Health New York
- AMER, S., JAMES, C., AL-HUSSAINI, T. K. & MOHAMED, A. A. 2020. Assessment of Circulating Anti-Mullerian Hormone in Women Using Hormonal Contraception: A Systematic Review. *J Womens Health (Larchmt)*, 29, 100-110.
- AN, L. S., YUAN, X. H., HU, Y., SHI, Z. Y., LIU, X. Q., QIN, L., WU, G. Q., HAN, W., WANG, Y. Q. & MA, X. 2012. Progesterone production requires activation of caspase-3 in preovulatory granulosa cells in a serum starvation model. *Steroids*, 77, 1477-82.
- ANCKAERT, E., OKTEM, M., THIES, A., COHEN-BACRIE, M., DAAN, N. M., SCHIETTECATTE, J., MULLER, C., TOPCU, D., GRONING, A., TERNAUX, F., ENGEL, C., ENGELMANN, S. & MILCZYNSKI, C. 2016. Multicenter analytical performance evaluation of a fully automated anti-Mullerian hormone assay and reference interval determination. *Clin Biochem*, 49, 260-7.

- ANDERSEN, C. Y. & LOSSL, K. 2008. Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-Mullerian hormone and inhibin-B. *Fertil Steril*, 89, 1760-5.
- APTER, D., GEMZELL-DANIELSSON, K., HAUCK, B., ROSEN, K. & ZURTH, C. 2014. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. *Fertil Steril*, 101, 1656-62 e1-4.
- BAHAMONDES, L. & BAHAMONDES, M. V. 2014. New and emerging contraceptives: a state-of-the-art review. *Int J Womens Health*, 6, 221-34.
- BAHAMONDES, L., BRACHE, V., MEIRIK, O., ALI, M., HABIB, N., LANDOULSI, S. & WOMEN, W. H. O. S. G. O. C. I. F. 2015. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. *Hum Reprod*, 30, 2527-38.
- BAHAMONDES, L., FERNANDES, A., MONTEIRO, I. & BAHAMONDES, M. V. 2020. Long-acting reversible contraceptive (LARCs) methods. *Best Pract Res Clin Obstet Gynaecol*, 66, 28-40.
- BARBOSA, I. C., MAIA, H., JR., COUTINHO, E., LOPES, R., LOPES, A. C., NORONHA, C. & BOTTO, A. 2006. Effects of a single Silastic contraceptive implant containing norgestrel acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. *Contraception*, 74, 492-7.
- BARNHART, K. T. & SCHREIBER, C. A. 2009. Return to fertility following discontinuation of oral contraceptives. *Fertil Steril*, 91, 659-63.
- BEKSINSKA, M., ISSEMA, R., BEESHAM, I., LALBAHADUR, T., THOMAS, K., MORRISON, C., HOFMEYR, G. J., STEYN, P. S., MUGO, N., PALANEE-PHILLIPS, T., AHMED, K., NAIR, G., BAETEN, J. M. & SMIT, J. 2021. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. *EClinicalMedicine*, 34, 100800.
- BENNINK, H. J. 2000. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. *Eur J Contracept Reprod Health Care*, 5 Suppl 2, 12-20.
- BENTZEN, J. G., FORMAN, J. L., PINBORG, A., LIDEGAARD, O., LARSEN, E. C., FRIIS-HANSEN, L., JOHANNSEN, T. H. & NYBOE ANDERSEN, A. 2012. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. *Reprod Biomed Online*, 25, 612-9.
- BERENSON, A. B., TAN, A. & HIRTH, J. M. 2015. Complications and continuation rates associated with 2 types of long-acting contraception. *Am J Obstet Gynecol*, 212, 761 e1-8.
- BERGADA, I., MILANI, C., BEDECARRAS, P., ANDREONE, L., ROPELATO, M. G., GOTTLIEB, S., BERGADA, C., CAMPO, S. & REY, R. A. 2006. Time course of the serum gonadotropin surge, inhibins, and anti-Mullerian hormone in normal newborn males during the first month of life. *J Clin Endocrinol Metab*, 91, 4092-8.

- BERNARDI, L. A., WEISS, M. S., WALDO, A., HARMON, Q., CARNETHON, M. R., BAIRD, D. D., WISE, L. A. & MARSH, E. E. 2021. Duration, recency, and type of hormonal contraceptive use and antimullerian hormone levels. *Fertil Steril*, 116, 208-217.
- BIRCH PETERSEN, K., HVIDMAN, H. W., FORMAN, J. L., PINBORG, A., LARSEN, E. C., MACKLON, K. T., SYLVEST, R. & ANDERSEN, A. N. 2015. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. *Hum Reprod*, 30, 2364-75.
- BLUMENTHAL, P. D., GEMZELL-DANIELSSON, K. & MARINTCHEVA-PETROVA, M. 2008. Tolerability and clinical safety of Implanon. *Eur J Contracept Reprod Health Care*, 13 Suppl 1, 29-36.
- BOOZALIS, A., TUTLAM, N. T., CHRISMAN ROBBINS, C. & PEIPERT, J. F. 2016. Sexual Desire and Hormonal Contraception. *Obstet Gynecol*, 127, 563-572.
- BOUQUIER, J., FULDA, V., BATS, A. S., LECURU, F. & HUCHON, C. 2012. A life-threatening ectopic pregnancy with etonogestrel implant. *Contraception*, 85, 215-7.
- BRACHE, V., FAUNDES, A., ALVAREZ, F. & COCHON, L. 2002. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. *Contraception*, 65, 63-74.
- BROEKMANS, F. J., VISSER, J. A., LAVEN, J. S., BROER, S. L., THEMMEN, A. P. & FAUSER, B. C. 2008. Anti-Mullerian hormone and ovarian dysfunction. *Trends Endocrinol Metab*, 19, 340-7.
- BROER, S. L., EIJKEMANS, M. J., SCHEFFER, G. J., VAN ROOIJ, I. A., DE VET, A., THEMMEN, A. P., LAVEN, J. S., DE JONG, F. H., TE VELDE, E. R., FAUSER, B. C. & BROEKMANS, F. J. 2011. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. *J Clin Endocrinol Metab*, 96, 2532-9.
- BUYUK, E., SEIFER, D. B., ILLIONS, E., GRAZI, R. V. & LIEMAN, H. 2011. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. *Fertil Steril*, 95, 2364-8.
- CATTEAU-JONARD, S., ROUX, M., DUMONT, A., DELESALLE, A. S., ROBIN, G. & DEWAILLY, D. 2017. Anti-Mullerian hormone concentrations and parity in fertile women: the model of oocyte donors. *Reprod Biomed Online*, 34, 541-545.
- CROXATTO, H. B. & MAKARAINEN, L. 1998. The pharmacodynamics and efficacy of Implanon. An overview of the data. *Contraception*, 58, 91S-97S.
- CURTIS, K. M., RAVI, A. & GAFFIELD, M. L. 2009. Progestogen-only contraceptive use in obese women. *Contraception*, 80, 346-54.
- DARNEY, P., PATEL, A., ROSEN, K., SHAPIRO, L. S. & KAUNITZ, A. M. 2009. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. *Fertil Steril*, 91, 1646-53.
- DARNEY, P. D. 1994. Hormonal implants: contraception for a new century. *Am J Obstet Gynecol*, 170, 1536-43.

- DAYAL, M., SAGAR, S., CHAURASIA, A. & SINGH, U. 2014. Anti-mullerian hormone: a new marker of ovarian function. *J Obstet Gynaecol India*, 64, 130-3.
- DEPMANN, M., EIJKEMANS, M. J., BROER, S. L., SCHEFFER, G. J., VAN ROOIJ, I. A., LAVEN, J. S. & BROEKMANS, F. J. 2016. Does anti-Mullerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. *Hum Reprod*, 31, 1579-87.
- DEWAILLY, D., ANDERSEN, C. Y., BALEN, A., BROEKMANS, F., DILAVER, N., FANCHIN, R., GRIESINGER, G., KELSEY, T. W., LA MARCA, A., LAMBALK, C., MASON, H., NELSON, S. M., VISSER, J. A., WALLACE, W. H. & ANDERSON, R. A. 2014. The physiology and clinical utility of anti-Mullerian hormone in women. *Hum Reprod Update*, 20, 370-85.
- DEWAILLY, D. & LAVEN, J. 2019. AMH as the primary marker for fertility. *Eur J Endocrinol*, 181, D45-D51.
- DIAZ, S., PAVEZ, M., MOO-YOUNG, A. J., BARDIN, C. W. & CROXATTO, H. B. 1991. Clinical trial with 3-keto-desogestrel subdermal implants. *Contraception*, 44, 393-408.
- DOLLEMAN, M., FADDY, M. J., VAN DISSELDORP, J., VAN DER SCHOUW, Y. T., MESSOW, C. M., LEADER, B., PEETERS, P. H., MCCONNACHIE, A., NELSON, S. M. & BROEKMANS, F. J. 2013a. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. *J Clin Endocrinol Metab*, 98, 1946-53.
- DOLLEMAN, M., VERSCHUREN, W. M., EIJKEMANS, M. J., DOLLE, M. E., JANSEN, E. H., BROEKMANS, F. J. & VAN DER SCHOUW, Y. T. 2013b. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. *J Clin Endocrinol Metab*, 98, 2106-15.
- DURLINGER, A. L., GRUIJTERS, M. J., KRAMER, P., KARELS, B., KUMAR, T. R., MATZUK, M. M., ROSE, U. M., DE JONG, F. H., UILENBROEK, J. T., GROOTEGOED, J. A. & THEMMEN, A. P. 2001. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. *Endocrinology*, 142, 4891-9.
- DURLINGER, A. L., KRAMER, P., KARELS, B., DE JONG, F. H., UILENBROEK, J. T., GROOTEGOED, J. A. & THEMMEN, A. P. 1999. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. *Endocrinology*, 140, 5789-96.
- ENDRIKAT, J., GERLINGER, C., RICHARD, S., ROSENBAUM, P. & DUSTERBERG, B. 2011. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. *Contraception*, 84, 549-57.
- FANCHIN, R., TAIEB, J., LOZANO, D. H., DUCOT, B., FRYDMAN, R. & BOUYER, J. 2005. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. *Hum Reprod*, 20, 923-7.

- FAUNDES, A., ALVAREZ-SANCHEZ, F., BRACHE, V., JIMENEZ, E. & TEJADA, A. S. 1991. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants. *Adv Contracept*, 7, 85-94.
- FOSTER, D. G., ROSTOVTSEVA, D. P., BRINDIS, C. D., BIGGS, M. A., HULETT, D. & DARNEY, P. D. 2009. Cost savings from the provision of specific methods of contraception in a publicly funded program. *Am J Public Health*, 99, 446-51.
- FRASER, I. S., TIITINEN, A., AFFANDI, B., BRACHE, V., CROXATTO, H. B., DIAZ, S., GINSBURG, J., GU, S., HOLMA, P., JOHANSSON, E., MEIRIK, O., MISHELL, D. R., JR., NASH, H. A., VON SCHOULTZ, B. & SIVIN, I. 1998. Norplant consensus statement and background review. *Contraception*, 57, 1-9.
- FREEMAN, E. W., GRACIA, C. R., SAMMEL, M. D., LIN, H., LIM, L. C. & STRAUSS, J. F., 3RD 2007. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. *Fertil Steril*, 87, 101-6.
- FREEMAN, E. W., SAMMEL, M. D., LIN, H. & GRACIA, C. R. 2012. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. *J Clin Endocrinol Metab*, 97, 1673-80.
- GARCIA-VELASCO, J. A., MORENO, L., PACHECO, A., GUILLEN, A., DUQUE, L., REQUENA, A. & PELLICER, A. 2005. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. *Fertil Steril*, 84, 82-7.
- GEBREMEDHIN, S. & ASEFA, A. 2018. Association between type of contraceptive use and haemoglobin status among women of reproductive age in 24 sub-Saharan Africa countries. *BMJ Sex Reprod Health*.
- GIRUM, T. & WASIE, A. 2018. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. *Contracept Reprod Med*, 3, 9.
- GLASIER, A. 2002. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. *Contraception*, 65, 29-37.
- GOUGEON, A. 1998. Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. *Maturitas*, 30, 137-42.
- GROSSMAN, M. P., NAKAJIMA, S. T., FALLAT, M. E. & SIOW, Y. 2008. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. *Fertil Steril*, 89, 1364-70.
- GUNARDI, B. A. E. R. 2014. Serum levonorgestrel concentration and cervical mucus viscosity after six months of monoplant® implantation. *Medical Journal of Indonesia*
- GWINNELL, E. 2007. Expulsion of Implanon. *J Fam Plann Reprod Health Care*, 33, 211.
- HADLOW, N., LONGHURST, K., MCCLEMENTS, A., NATALWALA, J., BROWN, S. J. & MATSON, P. L. 2013. Variation in antimullerian

- hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. *Fertil Steril*, 99, 1791-7.
- HANSEN, K. R., HODNETT, G. M., KNOWLTON, N. & CRAIG, L. B. 2011. Correlation of ovarian reserve tests with histologically determined primordial follicle number. *Fertil Steril*, 95, 170-5.
- HARITON, E., SHIRAZI, T. N., DOUGLAS, N. C., HERSHLAG, A. & BRIGGS, S. F. 2021. Anti-Mullerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. *Am J Obstet Gynecol*.
- HARRISON-WOOLRYCH, M. & HILL, R. 2005. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. *Contraception*, 71, 306-8.
- HEHENKAMP, W. J., LOOMAN, C. W., THEMME, A. P., DE JONG, F. H., TE VELDE, E. R. & BROEKMANS, F. J. 2006. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. *J Clin Endocrinol Metab*, 91, 4057-63.
- HERAWATI, S. 2019. Anti-Mullerian Hormone (AMH) as a Novel Marker for Ovarian Function: A Review. *Bali Medical Journal*.
- HERVEY, E. & HERVEY, G. R. 1967. The effects of progesterone on body weight and composition in the rat. *J Endocrinol*, 37, 361-81.
- HICKEY, M. & D'ARCANGUES, C. 2002. Vaginal bleeding disturbances and implantable contraceptives. *Contraception*, 65, 75-84.
- HICKEY, M., FRASER, I., DWARTE, D. & GRAHAM, S. 1996. Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study. *Hum Reprod*, 11 Suppl 2, 35-44.
- HIDALGO, M. M., LISONDO, C., JULIATO, C. T., ESPEJO-ARCE, X., MONTEIRO, I. & BAHAMONDES, L. 2006. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. *Contraception*, 73, 532-6.
- HOHMANN, H. & CREININ, M. D. 2007. The contraceptive implant. *Clin Obstet Gynecol*, 50, 907-17.
- JACOBSTEIN, R. & POLIS, C. B. 2014. Progestin-only contraception: injectables and implants. *Best Pract Res Clin Obstet Gynaecol*, 28, 795-806.
- JAMIL, Z., FATIMA, S. S., CHEEMA, Z., BAIG, S. & CHOUDHARY, R. A. 2016. Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone. *J Res Med Sci*, 21, 100.
- JEPPESEN, J. V., ANDERSON, R. A., KELSEY, T. W., CHRISTIANSEN, S. L., KRISTENSEN, S. G., JAYAPRAKASAN, K., RAINE-FENNING, N., CAMPBELL, B. K. & YDING ANDERSEN, C. 2013. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. *Mol Hum Reprod*, 19, 519-27.
- JEWETT, B. E., WALLACE, R. L. & SARKODIE, O. 2018. Pseudotumor Cerebri Following Nexplanon(R) Implantation. *Cureus*, 10, e2648.
- KALLIO, S., PUURUNEN, J., RUOKONEN, A., VASKIVUO, T., PILTONEN, T. & TAPANAINEN, J. S. 2013. Antimullerian hormone levels decrease in

- women using combined contraception independently of administration route. *Fertil Steril*, 99, 1305-10.
- KELSEY, T. W., ANDERSON, R. A., WRIGHT, P., NELSON, S. M. & WALLACE, W. H. 2012. Data-driven assessment of the human ovarian reserve. *Mol Hum Reprod*, 18, 79-87.
- KELSEY, T. W., WRIGHT, P., NELSON, S. M., ANDERSON, R. A. & WALLACE, W. H. 2011. A validated model of serum anti-mullerian hormone from conception to menopause. *PLoS One*, 6, e22024.
- KEMENKES 2020. *Profil Kesehatan Indonesia Tahun 2019*.
- KLAVON, S. L. & GRUBB, G. S. 1990. Insertion site complications during the first year of NORPLANT use. *Contraception*, 41, 27-37.
- KUCERA, R., ULCOVA-GALLOVA, Z. & TOPOLCAN, O. 2016. Effect of long-term using of hormonal contraception on anti-Mullerian hormone secretion. *Gynecol Endocrinol*, 32, 383-5.
- LA MARCA, A., SIGHINOLFI, G., GIULINI, S., TRAGLIA, M., ARGENTO, C., SALA, C., MASCIULLO, C., VOLPE, A. & TONIOLO, D. 2010. Normal serum concentrations of anti-Mullerian hormone in women with regular menstrual cycles. *Reprod Biomed Online*, 21, 463-9.
- LANCIOTTI, L., COFINI, M., LEONARDI, A., PENTA, L. & ESPOSITO, S. 2018. Up-To-Date Review About Minipuberty and Overview on Hypothalamic-Pituitary-Gonadal Axis Activation in Fetal and Neonatal Life. *Front Endocrinol (Lausanne)*, 9, 410.
- LANDERSOE, S. K., BIRCH PETERSEN, K., SORENSEN, A. L., LARSEN, E. C., MARTINUSSEN, T., LUNDING, S. A., KROMAN, M. S., NIELSEN, H. S. & NYBOE ANDERSEN, A. 2020a. Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives. *Reprod Biomed Online*, 40, 176-186.
- LANDERSOE, S. K., FORMAN, J. L., BIRCH PETERSEN, K., LARSEN, E. C., NOHR, B., HVIDMAN, H. W., NIELSEN, H. S. & NYBOE ANDERSEN, A. 2020b. Ovarian reserve markers in women using various hormonal contraceptives. *Eur J Contracept Reprod Health Care*, 25, 65-71.
- LANDERSOE, S. K., PETERSEN, K. B., VASSARD, D., LARSEN, E. C., NIELSEN, H. S., PINBORG, A., NOHR, B., NYBOE ANDERSEN, A. & SCHMIDT, L. 2019. Concerns on future fertility among users and past-users of combined oral contraceptives: a questionnaire survey. *Eur J Contracept Reprod Health Care*, 24, 347-355.
- LANGE, J., TEAL, S. & TOCCE, K. 2014. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report. *J Med Case Rep*, 8, 43.
- LE, J. & TSOUROUNIS, C. 2001. Implanon: a critical review. *Ann Pharmacother*, 35, 329-36.
- LEADER, B. & BAKER, V. L. 2014. Maximizing the clinical utility of antimullerian hormone testing in women's health. *Curr Opin Obstet Gynecol*, 26, 226-36.

- LEFEBVRE, R., HOM, M., LELAND, H. & STEVANOVIC, M. 2018. Peripheral nerve injury with Nexplanon removal: case report and review of the literature. *Contracept Reprod Med*, 3, 15.
- LETICEE, N., VIARD, J. P., YAMGNANE, A., KARMOCHKINE, M. & BENACHI, A. 2012. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. *Contraception*, 85, 425-7.
- LEVINE, J. P., SINOFSKY, F. E., CHRIST, M. F. & IMPLANON, U. S. S. G. 2008. Assessment of Implanon insertion and removal. *Contraception*, 78, 409-17.
- LINDHARDT JOHANSEN, M., HAGEN, C. P., JOHANNSEN, T. H., MAIN, K. M., PICARD, J. Y., JORGENSEN, A., RAJPERT-DE MEYTS, E. & JUUL, A. 2013. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. *Int J Endocrinol*, 2013, 198698.
- LOPEZ, L. M., BERNHOLC, A., CHEN, M., GREY, T. W., OTTERNESS, C., WESTHOFF, C., EDELMAN, A. & HELMERHORST, F. M. 2016a. Hormonal contraceptives for contraception in overweight or obese women. *Cochrane Database Syst Rev*, CD008452.
- LOPEZ, L. M., RAMESH, S., CHEN, M., EDELMAN, A., OTTERNESS, C., TRUSSELL, J. & HELMERHORST, F. M. 2016b. Progestin-only contraceptives: effects on weight. *Cochrane Database Syst Rev*, 2016, CD008815.
- LORTSCHER, D., ADMANI, S., SATUR, N. & EICHENFIELD, L. F. 2016. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. *J Drugs Dermatol*, 15, 670-4.
- MANSOUR, D., GEMZELL-DANIELSSON, K., INKI, P. & JENSEN, J. T. 2011. Fertility after discontinuation of contraception: a comprehensive review of the literature. *Contraception*, 84, 465-77.
- MARIA, S. M., H; ABADI, A; THEODORUS 2020. Effects of Levonorgestrel Implants of One Rod and Two Rod on Lipid Profile, Follicle Stimulating Hormone (FSH), and Estradiol Levels in Acceptors. *Indonesian Journal of Obstetrics and Gynecology*
- MCNICHOLAS, C., SWOR, E., WAN, L. & PEIPERT, J. F. 2017. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. *Am J Obstet Gynecol*, 216, 586 e1-586 e6.
- MEIRIK, O., FRASER, I. S., D'ARCANGUES, C. & WOMEN, W. H. O. C. O. I. C. F. 2003. Implantable contraceptives for women. *Hum Reprod Update*, 9, 49-59.
- MELADO, L., LAWRENZ, B., SIBAL, J., ABU, E., COUGHLAN, C., NAVARRO, A. T. & FATEMI, H. M. 2018. Anti-mullerian Hormone During Natural Cycle Presents Significant Intra and Intercycle Variations When Measured With Fully Automated Assay. *Front Endocrinol (Lausanne)*, 9, 686.

- MERHI, Z., BUYUK, E., BERGER, D. S., ZAPANTIS, A., ISRAEL, D. D., CHUA, S., JR. & JINDAL, S. 2013. Leptin suppresses anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF. *Hum Reprod*, 28, 1661-9.
- MIKKELSEN, E. M., RIIS, A. H., WISE, L. A., HATCH, E. E., ROTHMAN, K. J. & SORENSEN, H. T. 2013. Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study. *Hum Reprod*, 28, 1398-405.
- MILLS, M., RINDFUSS, R. R., MCDONALD, P., TE VELDE, E., REPRODUCTION, E. & SOCIETY TASK, F. 2011. Why do people postpone parenthood? Reasons and social policy incentives. *Hum Reprod Update*, 17, 848-60.
- MISHELL, D. S. A. D. R. 2016. *The handbook of contraception: A guide for practical management*
- MOINI, A., HEDAYATSHODEH, M., HOSSEINI, R. & RASTAD, H. 2016. Association between parity and ovarian reserve in reproductive age women. *Eur J Obstet Gynecol Reprod Biol*, 207, 184-187.
- MORAES, L. G., MARCHI, N. M., PITOLI, A. C., HIDALGO, M. M., SILVEIRA, C., MODESTO, W. & BAHAMONDES, L. 2016. Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use. *Eur J Contracept Reprod Health Care*, 21, 318-22.
- MORAY, K. V., CHAURASIA, H., SACHIN, O. & JOSHI, B. 2021. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. *Reprod Health*, 18, 4.
- MOSLEHI, N., SHAB-BIDAR, S., RAMEZANI TEHRANI, F., MIRMIRAN, P. & AZIZI, F. 2018. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. *Menopause*, 25, 1046-1055.
- MOY, V., JINDAL, S., LIEMAN, H. & BUYUK, E. 2015. Obesity adversely affects serum anti-mullerian hormone (AMH) levels in Caucasian women. *J Assist Reprod Genet*, 32, 1305-11.
- NAIR, S., SLAUGHTER, J. C., TERRY, J. G., APPIAH, D., EBONG, I., WANG, E., SISCOVICK, D. S., STERNFELD, B., SCHREINER, P. J., LEWIS, C. E., KABAGAMBE, E. K. & WELLONS, M. F. 2015. Anti-mullerian hormone (AMH) is associated with natural menopause in a population-based sample: The CARDIA Women's Study. *Maturitas*, 81, 493-8.
- NIU, X., LUO, Q., WANG, C., ZHU, L. & HUANG, L. 2021. Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: Results from a prospective, observational study. *Medicine (Baltimore)*, 100, e24597.
- OVERBEEK, A., BROEKMANS, F. J., HEHENKAMP, W. J., WIJDEVELD, M. E., VAN DISSELDORP, J., VAN DULMEN-DEN BROEDER, E. & LAMBALK, C. B. 2012. Intra-cycle fluctuations of anti-Mullerian hormone

- in normal women with a regular cycle: a re-analysis. *Reprod Biomed Online*, 24, 664-9.
- PAM, V. C., MUSA, J., MUTIHIR, J. T., KARSHIMA, J. A., ANYAKA, C. U. & SAGAY, A. S. 2014. Body Weight Changes in Women Using Implanon in Jos, Nigeria. *Afr J Med Med Sci*, 43, 15-21.
- PATEL, R. C., MORRONI, C., SCARSI, K. K., SRIPIPATANA, T., KIARIE, J. & COHEN, C. R. 2017. Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. *J Int AIDS Soc*, 20, 21396.
- PEDROSO, C., MARTINS, I., PALMA, F. & MACHADO, A. I. 2015. Implant site Nexplanon reaction? *BMJ Case Rep*, 2015.
- POWER, J., FRENCH, R. & COWAN, F. 2007. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. *Cochrane Database Syst Rev*, CD001326.
- RAJPERT-DE MEYTS, E., JORGENSEN, N., GRAEM, N., MULLER, J., CATE, R. L. & SKAKKEBAEK, N. E. 1999. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. *J Clin Endocrinol Metab*, 84, 3836-44.
- RAMDHAN, R. C., SIMONDS, E., WILSON, C., LOUKAS, M., OSKOUIAN, R. J. & TUBBS, R. S. 2018. Complications of Subcutaneous Contraception: A Review. *Cureus*, 10, e2132.
- ROBKER, R. L., AKISON, L. K., BENNETT, B. D., THRUPP, P. N., CHURA, L. R., RUSSELL, D. L., LANE, M. & NORMAN, R. J. 2009. Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. *J Clin Endocrinol Metab*, 94, 1533-40.
- ROBKER, R. L., WU, L. L. & YANG, X. 2011. Inflammatory pathways linking obesity and ovarian dysfunction. *J Reprod Immunol*, 88, 142-8.
- ROCCA, M. L., PALUMBO, A. R., VISCONTI, F. & DI CARLO, C. 2021. Safety and Benefits of Contraceptives Implants: A Systematic Review. *Pharmaceuticals (Basel)*, 14.
- ROGERS, P. A., PLUNKETT, D. & AFFANDI, B. 2000. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. *Hum Reprod*, 15 Suppl 3, 78-84.
- SAIFUDDIN 2011. *Buku Panduan Praktis Pelayanan Kontrasepsi*, Jakarta, Yayasan Bina Pustaka Sarwono Prawirohardjo.
- SCHMIDT, H. & SCHWARZ, H. P. 2000. Serum concentrations of LH and FSH in the healthy newborn. *Eur J Endocrinol*, 143, 213-5.
- SCHMIDT, L., SOBOTKA, T., BENTZEN, J. G., NYBOE ANDERSEN, A., REPRODUCTION, E. & SOCIETY TASK, F. 2012. Demographic and medical consequences of the postponement of parenthood. *Hum Reprod Update*, 18, 29-43.

- SCHUH-HUERTA, S. M., JOHNSON, N. A., ROSEN, M. P., STERNFELD, B., CEDARS, M. I. & REIJO PERA, R. A. 2012. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. *Hum Reprod*, 27, 594-608.
- SEIDMAN, L., KROLL, R., HOWARD, B., RICCIOTTI, N., HSIEH, J. & WEISS, H. 2015. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. *Contraception*, 91, 495-502.
- SEIFER, D. B., GOLUB, E. T., LAMBERT-MESSERLIAN, G., BENNING, L., ANASTOS, K., WATTS, D. H., COHEN, M. H., KARIM, R., YOUNG, M. A., MINKOFF, H. & GREENBLATT, R. M. 2009. Variations in serum mullerian inhibiting substance between white, black, and Hispanic women. *Fertil Steril*, 92, 1674-8.
- SEIFER, D. B., MACLAUGHLIN, D. T., PENZIAS, A. S., BEHRMAN, H. R., ASMUNDSON, L., DONAHOE, P. K., HANING, R. V., JR. & FLYNN, S. D. 1993. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid mullerian-inhibiting substance and androgen content. *J Clin Endocrinol Metab*, 76, 711-4.
- SERATI, M., BOGANI, G., KUMAR, S., CROMI, A. & GHEZZI, F. 2015. Delayed-type hypersensitivity reaction against Nexplanon(R). *Contraception*, 91, 91-2.
- SHEIN-CHUNG CHOW, J. S., HANSHENG WANG, YULIYA LOKHNYGINA 2018. *Sample Size Calculations in Clinical Research*, Chapman and Hall/CRC.
- SIMMONS, K. B. & EDELMAN, A. B. 2016. Hormonal contraception and obesity. *Fertil Steril*, 106, 1282-1288.
- SIVIN, I. 1994. Contraception with NORPLANT implants. *Hum Reprod*, 9, 1818-26.
- SIVIN, I. 2003. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. *Drug Saf*, 26, 303-35.
- SIVIN, I., LAHTENMAKI, P., RANTA, S., DARNEY, P., KLAISLE, C., WAN, L., MISHELL, D. R., JR., LACARRA, M., VIEGAS, O. A., BILHAREUS, P., KOETSAWANG, S., PIYA-ANANT, M., DIAZ, S., PAVEZ, M., ALVAREZ, F., BRACHE, V., LAGUARDIA, K., NASH, H. & STERN, J. 1997. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. *Contraception*, 55, 81-5.
- SIVIN, I., MISHELL, D. R., JR., DARNEY, P., WAN, L. & CHRIST, M. 1998. Levonorgestrel capsule implants in the United States: a 5-year study. *Obstet Gynecol*, 92, 337-44.
- SIVIN, I., WAN, L., RANTA, S., ALVAREZ, F., BRACHE, V., MISHELL, D. R., JR., DARNEY, P., BISWAS, A., DIAZ, S., KIRIWAT, O., ANANT, M. P., KLAISLE, C., PAVEZ, M. & SCHECHTER, J. 2001. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. *Contraception*, 64, 43-9.
- SONG, S., CHEN, J. K., LU, C. H., YANG, P. J., YANG, Q. Y., FAN, B. C., HE, M. L., GUI, Y. L., LI, L. M. & FOTHERBY, K. 1993. Effects of different

- doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol. *Contraception*, 47, 527-37.
- SOWERS, M., MCCONNELL, D., GAST, K., ZHENG, H., NAN, B., MCCARTHY, J. D. & RANDOLPH, J. F. 2010. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. *Fertil Steril*, 94, 1482-1486.
- STEINER, A. Z., STANCZYK, F. Z., PATEL, S. & EDELMAN, A. 2010a. Antimullerian hormone and obesity: insights in oral contraceptive users. *Contraception*, 81, 245-8.
- STEINER, M. J., LOPEZ, L. M., GRIMES, D. A., CHENG, L., SHELTON, J., TRUSSELL, J., FARLEY, T. M. & DORFLINGER, L. 2010b. Sino-implant (II)--a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials. *Contraception*, 81, 197-201.
- SUNDARAM, A., VAUGHAN, B., KOST, K., BANKOLE, A., FINER, L., SINGH, S. & TRUSSELL, J. 2017. Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth. *Perspect Sex Reprod Health*, 49, 7-16.
- THAXTON, L. & LAVELANET, A. 2019. Systematic review of efficacy with extending contraceptive implant duration. *Int J Gynaecol Obstet*, 144, 2-8.
- THOMAS, A. G., JR. & LEMELLE, S. M. 1995. The Norplant System: where are we in 1995? *J Fam Pract*, 40, 125-8.
- TRUSSELL, J. 2011. Contraceptive failure in the United States. *Contraception*, 83, 397-404.
- TSEPELIDIS, S., DEVREKER, F., DEMEESTERE, I., FLAHAUT, A., GERVY, C. & ENGLERT, Y. 2007. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. *Hum Reprod*, 22, 1837-40.
- TUOK, D. K., GAWRON, L. M. & LAWSON, S. 2016. New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services. *Fertil Steril*, 106, 1273-1281.
- URBANCSEK, J. 1998. An integrated analysis of nonmenstrual adverse events with Implanon. *Contraception*, 58, 109S-115S.
- VAN DEN BERG, M. H., VAN DULMEN-DEN BROEDER, E., OVERBEEK, A., TWISK, J. W., SCHAT, R., VAN LEEUWEN, F. E., KASPERS, G. J. & LAMBALK, C. B. 2010. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. *Hum Reprod*, 25, 1520-7.
- VAN HEUSDEN, A. M., COELINGH BENNINK, H. J. & FAUSER, B. C. 2002. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives. *Clin Endocrinol (Oxf)*, 56, 509-17.
- VAN ROOIJ, I. A., BROEKMANS, F. J., SCHEFFER, G. J., LOOMAN, C. W., HABBEMA, J. D., DE JONG, F. H., FAUSER, B. J., THEMME, A. P. & TE VELDE, E. R. 2005. Serum antimullerian hormone levels best reflect

- the reproductive decline with age in normal women with proven fertility: a longitudinal study. *Fertil Steril*, 83, 979-87.
- VAN ROOIJ, I. A., BROEKMANS, F. J., TE VELDE, E. R., FAUSER, B. C., BANCSI, L. F., DE JONG, F. H. & THEMME, A. P. 2002. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. *Hum Reprod*, 17, 3065-71.
- VANDEVER, M. A., KUEHL, T. J., SULAK, P. J., WITT, I., COFFEE, A., WINCEK, T. J. & REAPE, K. Z. 2008. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. *Contraception*, 77, 162-70.
- VARMA, R. & MASCARENHAS, L. 2001. Endometrial effects of etonogestrel (Implanon) contraceptive implant. *Curr Opin Obstet Gynecol*, 13, 335-41.
- VILLAVICENCIO, J. & ALLEN, R. H. 2016. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. *Open Access J Contracept*, 7, 43-52.
- VISSER, J. A., DE JONG, F. H., LAVEN, J. S. & THEMME, A. P. 2006. Anti-Mullerian hormone: a new marker for ovarian function. *Reproduction*, 131, 1-9.
- VISSER, J. A. & THEMME, A. P. 2005. Anti-Mullerian hormone and folliculogenesis. *Mol Cell Endocrinol*, 234, 81-6.
- WATHONI, N. 2018. EVOLUTION OF CONTRACEPTIVE IMPLANTS: A REVIEW. *International Journal of Applied Pharmaceutics*.
- WEENEN, C., LAVEN, J. S., VON BERGH, A. R., CRANFIELD, M., GROOME, N. P., VISSER, J. A., KRAMER, P., FAUSER, B. C. & THEMME, A. P. 2004. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. *Mol Hum Reprod*, 10, 77-83.
- WHO 2018. Family Planning: A Global Handbook for Providers.
- WONODIREKSO, S., AU, C. L., HADISAPUTRA, W., AFFANDI, B. & ROGERS, P. A. 1993. Cytokeratins 8, 18 and 19 in endometrial epithelial cells during the normal menstrual cycle and in women receiving Norplant. *Contraception*, 48, 481-93.
- WUNDER, D. M., BERSINGER, N. A., YARED, M., KRETSCHMER, R. & BIRKHAUSER, M. H. 2008. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. *Fertil Steril*, 89, 927-33.